Total: $266.25M | ||||
Company |
Type Of |
Number |
Amount |
Investors; Placement Agents; Details (Date)@ |
Avanir |
Private placement ofstock |
6.1S |
$16.15 |
Shares were sold at $2.65 each in a registereddirect offering from a shelf registration; investingwere Xmark Funds, Federated Kaufmann, Jennison Associates LLC and OrbiMed Advisors LLC (10/18) |
CepTor Corp. |
Stock purchaseagreement |
N/A |
N/A |
Fusion Capital Fund II LLC agreed to purchase up to $20M of CepTor common stock over 40 months;CepTor has the right to sell Fusion $500,000 of stock per month at the market price (10/10) |
Cytokinetics |
Stock purchaseagreement |
N/A |
N/A |
Kingsbridge Capital Ltd. committed to purchase up to $75M of Cytokinetics' stock during the nextthree years, at times to be determined by Cytokinetics; Kingsbridge also got a five-year warrant tobuy up to 244,000 shares at $9.13 per share (10/28) |
Forbes |
Private placement ofconvertible notes andwarrants |
3.636S and 1.82W |
$6 |
The notes, which mature in October 2008, are convertible into about 3.6M shares at $1.65 pershare; the five-year warrants are exercisable at $2.06 per share; Merriman Curhan Ford & Co. wasplacement agent (10/27) |
Generex |
Warrants exercise |
ND |
$6.4 |
Investors paid $6.4M to exercise warrants to purchase an undisclosed number of shares (10/28) |
Gentium SpA |
Private placement ofstock and warrants |
1.55S and 0.62W |
$10.9 |
The American depository shares were sold at $7.05 each; warrants to ADSs are exercisable at$9.69 each; lead investors were funds managed by Great Point Partners LLC; Rodman & Renshaw LLCwas lead placement agent; Maxim Group LLC and I-Bankers Securities Inc. were co-agents (10/4) |
GlycoGenesys |
Stock purchaseagreement |
N/A |
N/A |
Fusion Capital Fund II LLC agreed to purchase up to $20M of GlycoGenesys stock over 25 months, attimes determined by GlycoGenesys (10/24) |
Hana |
Private placement ofstock and warrants |
3.68S and 0.737W |
$14.7 |
The shares were sold at $4 each; the five-year warrants are exercisable at $5.80 per share;investors included ProMed Management, Lehman Brothers, Pogue Capital Management, PerceptiveLife Sciences Fund, Atlas Equity, Mosaix Ventures, Coqui Capital and Panacea Asset Management;Oppenheimer & Co. Inc. was lead placement agent and Griffin Securities was co-agent (10/19) |
Helix |
Private placement ofstock and warrants |
2.34S and 2.34W |
C$4 (US$3.4) |
The securities were placed in Europe; each warrant is exercisable at C$2.39 per share until March 31,2008 (10/4) |
Inflazyme |
Restructuring of subsidiary |
N/A |
C$3.6 (US$3) |
Inflazyme raised a total of C$7M from the restructuring in September and then the sale of a subsidiary (10/27) |
La Jolla |
Private placement ofstock and warrants |
88S and 22W |
$66 |
Investing in the deal were Essex Woodlands Health Ventures Fund VI LP, Frazier Healthcare Ventures,Alejandro Gonzalez, Special Situations Funds, Domain Public Equity Partners LP and Sutter HillVentures; the five-year warrants are exercisable at $1 per share (10/7) |
Metabasis |
Private placement ofstock and warrants |
7S and 2.45W |
$41.3 |
The shares were sold at $5.86 each; the warrants are exercisable at $6.74 per share; investors paidan additional $0.125 per warrant; SG Cowen & Co. LLC was lead placement agent, and Rodman &Renshaw LLC served was co-agent (10/3) |
Mologen AG |
Private placement of stock |
0.684S |
€5.1 (US$6.1) |
The shares were placed with Absolute Capital Management at a 10-day average market price, which was not disclosed; the amount raised was estimated (10/12) |
Novelos |
Private placement of convertible stock and warrants |
N/A and ND |
$3 |
The 8% notes are convertible into stock at $1.65 per share; the five-year warrants are exercisable at $5 per share (10/3) |
Ortec |
Private placement of stock and warrants |
13.2S and 6.6W |
$3.3 |
The shares were sold at $0.25 each; the warrants are exercisable at $0.50per share (10/12) |
pSivida Ltd. |
Private placement of convertible notes and warrants |
N/A and 0.633W |
$15 |
The three-year, 8% notes are convertible into American depository receipts at $7.10 each; the six-year warrants are exercisable at $7.20 per ADR (10/6) |
Tercica Inc. |
Equity facility and warrant sale |
N/A and 0.26W |
N/A |
Kingsbridge Capital Ltd. committed to purchase up to $75M in stock over three years; Tercica will determine the timing and amounts; Kingsbridge also got a five-year warrant to purchase 260,000 shares at a 30% premium (10/14) |
Vasogen Inc. |
Private placement of convertible notes and warrants |
N/A and 3.33W |
$40 |
The two-year, 6.45% notes are convertible into common stock at $3 per share; the five-year warrants are exercisable at $3 per share (10/7) |
Vical Inc. |
Private placement of stock |
4.7S |
$22.6 |
The shares were sold at $4.80 each in a registered direct offering; Piper Jaffray & Co. was lead placement agent; Needham & Co. LLC and Rodman & Renshaw LLC were co-placement agents (10/12) |
VioQuest |
Private placement of stock and warrants |
11.2S and 4.5W |
$8.4 |
The shares were sold concurrently with its merger with Greenwich Therapeutics; the five-year warrants are exercisable at $1 per share; Paramount BioCapital Inc. was placement agent (10/19) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.